Lilly’s Emgality (galcanezumab) recommended by NICE as migraine preventative
The UK's NICE has recommended Emgality (galcanezumab) for the prevention of migraine in adults with episodic and chronic migraine.
List view / Grid view
News
Pharma supply chain still highly vulnerable to COVID-19 pandemic, says research
Report reveals global pharma supply chain leaders are afraid of the vulnerabilities in the end-to-end supply chain as the COVID-19 pandemic continues.
CVN058 shows promise in Phase Ib schizophrenia cognition study
A single dose of CVN058 was able to normalise brainwaves being used as a biomarker for cognitive impairment associated with schizophrenia.
EDQM releases new guidelines for COVID-19 vaccine quality testing
The European Directorate for the Quality of Medicines & Healthcare has announced three new guidelines outlining how to test the quality of COVID-19 vaccines.
Oxford COVID-19 vaccine triggers robust immune response in older adults, study shows
The University of Oxford and AstraZeneca COVID-19 vaccine candidate is effective in healthy adults aged 56-69 and those over 70 years of age, a Phase II study has demonstrated.
BNT162b2 vaccine is 95 percent effective against COVID-19, finds final efficacy analysis
The concluded Phase III study of BNT162b2 met all primary efficacy endpoints, with a consistent 95 percent efficacy across all patient populations.
Drug Safety Research Unit says repurposed drugs for COVID-19 still require a lot of testing
The DSRU said that global collaboration would be required to successfully expedite the necessary safety and efficacy evaluations for repurposed drugs to be used in COVID-19 patients.
COVID-19 is benefiting contract manufacturing services, suggest reports
Reports have found that the COVID-19 pandemic is providing new opportunities for contract and development manufacturing organisations (CDMOs).
Lateral flow assay market set to be worth $10.2 billion in 2025
Rising at a CAGR of 4.5 percent, the lateral flow assays market is projected increase due to the high prevalence of infectious diseases worldwide.
PhRMA announces new principles on clinical trial diversity
New principles on diversity in clinical trials in the US have been released to address systemic issues that deter people from participating in studies.
Microbial contract biomanufacturing market to be worth $9.3 billion by 2030
A new analysis suggests that Europe and North America will capture more than 80 percent of the $9.3 billion market by 2030.
J&J initiates second Phase III trial of COVID-19 vaccine candidate
J&J has initiated a global Phase III clinical trial to study JNJ-78436735, a vaccine candidate for the prevention of COVID-19.
EMA releases safety monitoring plan for COVID-19 vaccines
The EMA's safety monitoring plan outlines how new information after authorisation of COVID-19 vaccines will be collected and reviewed.
EMA initiates rolling review of Moderna’s COVID-19 vaccine
The rolling review will shorten the approval timeframe by evaluating data on the safety, efficacy and quality of the mRNA-1273 vaccine as it becomes available.
WHO lists first vaccine for emergency use
The nOPV2 vaccine has received emergency use listing and will be used to combat outbreaks of circulating vaccine-derived polio viruses (cVDPVs).
